Antitrust

$275M Sandoz and Fougera Antitrust Class Action Settlement

$275M Sandoz and Fougera Antitrust Class Action Settlement — Antitrust class action lawsuit

Case Overview

Sandoz Inc. and Fougera Pharmaceuticals Inc. have reached a settlement totaling $275 million to resolve claims that they participated in a conspiracy to raise and fix the prices of generic medications. This settlement is intended to benefit consumers and third-party payers who purchased, paid for, or reimbursed for generic drugs from these companies during the period spanning May 1, 2009, through December 31, 2019.

The plaintiffs in this multidistrict litigation alleged that generic drug manufacturers, including Sandoz and Fougera, colluded to manipulate and stabilize the pricing of generic drugs, which allegedly resulted in consumers and third-party payers overpaying for these necessary medications. Sandoz, an independent Swiss generic pharmaceuticals manufacturer, and its parent entity, Fougera, have not admitted any wrongdoing regarding these allegations.

Under the terms of the settlement, class members are eligible to receive a cash payment based on the amount they paid for covered drugs during the specified time frame; those who paid more will receive a larger portion of the fund. To claim benefits, individuals must submit a valid claim form by the deadline of November 9, 2026.

Who May Qualify

All persons and entities in the 50 United States (excluding Indiana and Ohio), the District of Columbia, Puerto Rico, and the U.S. Virgin Islands that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price for any named generic drugs, other than for resale, from May 1, 2009, to December 31, 2019.

Frequently Asked Questions

Who is eligible for this settlement?

The settlement benefits all persons and entities located in the 50 United States (with exceptions for Indiana and Ohio), the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. Eligibility requires having indirectly purchased, paid for, or provided reimbursement for named generic drugs, other than for resale, between May 1, 2009, and December 31, 2019.

What information do I need to prove my claim?

Consumers and third-party payers must provide specific details for each prescription, including the name of the pharmacy or mail-order pharmacy, the purchase date, the prescription number, the total out-of-pocket amount paid, and any amount paid by their health insurance plan.

What is the deadline to file a claim?

Class members must submit a valid claim form by November 9, 2026, to be considered for settlement benefits.

Related Cases

$117M Pork Price-Fixing Class Action Settlement — Antitrust class action lawsuit

$117M Pork Price-Fixing Class Action Settlement

Current
Antitrust
Pork producers agreed to a settlement to resolve allegations that they conspired to artificially inflate the price of pork products. This settlement benefits consumers who purchased specific types of raw pork in certain states during a defined time frame.
Visa, Mastercard Non-Bank ATM Surcharge Settlement — Antitrust class action lawsuit

Visa, Mastercard Non-Bank ATM Surcharge Settlement

Current
Antitrust
Visa and Mastercard agreed to a combined $167.5 million settlement to resolve allegations that they violated antitrust laws by allowing differential ATM surcharges. This settlement benefits individuals who were charged access fees for cash withdrawals at independent ATMs between October 24, 2007, and August 14, 2026, and were not fully reimbursed by their bank.
National Association of Realtors (NAR) Commission Antitrust Settlement — Antitrust class action lawsuit

National Association of Realtors (NAR) Commission Antitrust Settlement

Past
Antitrust
A landmark antitrust verdict and $418 million settlement against the National Association of Realtors found that standard commission-sharing rules illegally inflated real estate agent commissions paid by home sellers across the United States.